ArticleEuropean journal of nuclear medicine and molecular imaging2023
High in-vivo stability in preclinical and first-in-human experiments with [
Abstract readComment
In one paragraph
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Detection of HER2 expression usingBreast cancer research : BCR · 2024Trial
- Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3-Targeted Single-Domain Antibody PET.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- ImmunoPET imaging of c-Met using a nanobody-based tracer [European journal of nuclear medicine and molecular imaging · 2025Article
- A high-affinity CEA-targeted nanobody forJournal of nanobiotechnology · 2025Article
- Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers.European journal of nuclear medicine and molecular imaging · 2025Article
- Review
- Molecular imaging of renal cell carcinomas: ready for prime time.Nature reviews. Urology · 2025Review
- Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy.Biomolecules · 2025Review
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Preclinical evaluation and pilot clinical study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Recent advancements in new tracers from first-in-human studies.Annals of nuclear medicine · 2024Review
- Optimized method for fluorine-18 radiolabeling of Affibody molecules using RESCA.EJNMMI radiopharmacy and chemistry · 2024Article
- Cyclohexanediamine Triazole (CHDT) Functionalization Enables Labeling of Target Molecules with AlBioconjugate chemistry · 2024Article
- Article
- Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule.iScience · 2024Article
- Radiosynthesis and preclinical evaluations of [American journal of nuclear medicine and molecular imaging · 2024Article
- Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.Immunotherapy advances · 2024Review
- Preclinical evaluation and pilot clinical study of [European journal of nuclear medicine and molecular imaging · 2023Article
- Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside.European journal of nuclear medicine and molecular imaging · 2023Article
- Ultrasensitive Electrochemical Immunosensors Using Nanobodies as Biocompatible Sniffer Tools of Agricultural Contaminants and Human Disease Biomarkers.Micromachines · 2023Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
11 authors at 2 institutions in 2 countries.
Xue Qin *Guizhou University School of Medicine, Guizhou University, Guiyang, 550025, China.
Xiaoyi Guo *Key Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Tianyu LiuMedical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, 100191, China.
Liqiang LiKey Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Nina ZhouKey Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Xiaopan MaGuizhou University School of Medicine, Guizhou University, Guiyang, 550025, China.
Xiangxi MengKey Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Jiayue LiuKey Laboratory of Carcinogenesis and Translational Research, (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Hua ZhuGuizhou University School of Medicine, Guizhou University, Guiyang, 550025, China. zhuhuananjing@163.com.
Bing JiaMedical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, 100191, China. jiabing@bjmu.edu.cn.
Zhi YangGuizhou University School of Medicine, Guizhou University, Guiyang, 550025, China. pekyz@163.com.ORCID http://orcid.org/0000-0003-2084-5193
Peking University · CNGuizhou University · CN
Funding
Alpha Foundation for the Improvement of Mine Safety and Health 2022-2Z-2155)Alpha Foundation for the Improvement of Mine Safety and Health (No.2022-2Z-2154Beijing Municipal Administration of Hospitals-Yang fan Project (ZYLX201816), Science Foundation of Peking University Cancer Hospital (No.2021-4)Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (DFL20191102)National Outstanding Youth Science Fund Project of National Natural Science Foundation of China 82172006)National Outstanding Youth Science Fund Project of National Natural Science Foundation of China (projects 81871416Natural Science Foundation of Beijing Municipality (No.2021-4)Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan (2021-1)The Pilot Project (4 th Round) to Reform Public Development of Beijing Municipal Medical Research Institute 2021-1)
Abstract
purpose[
methodsMIRC213 was produced by E. coli and conjugated with ( ±)-H
resultsMIRC213 was produced with > 95% purity and modified with RESCA to obtain RESCA-MIRC213. [
conclusions[
Indexed as
Breast NeoplasmsPositron Emission Tomography Computed TomographyAnimalsCell Line, TumorEscherichia coliFemaleHumansMicePositron-Emission TomographyRadiopharmaceuticalsTissue DistributionRadiopharmaceuticals[18F]AlF-RESCA18F-labelingAnti-HER2 nanobodyFirst-in-humanPET
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.